Primary-care prescribing of anti-osteoporotic-type medications following hospitalisation for fractures
- 80 Downloads
We examined the prescribing of antiosteoporotic medications pre- and post hospital admission in patients with fragility fractures as well as factors associated with prescribing of these treatments following admission.
We identified all patients aged ≥55 years at a large teaching hospital between 2005 and 2008 with a fracture using the Hospital In-Patient Enquiry (HIPE) system. These data were linked to prescribing data from the Health Service Executive Primary Care Reimbursement Services (HSE-PCRS) scheme before and after discharge (821 patients). Logistic regression analysis was used to examine the likelihood of prescription of antiosteoporotic medication pre- and post discharge in relation to year of discharge, age, gender, and type of fracture.
Prescribing of antiosteoporotic treatment before fracture increased from 2.6% [95% confidence interval (CI) 2.23–2.93%] in 2005 to 10.6% (95% CI 9.32–11.86) by 2008, whereas post fracture prescribing increased from 11% (95% CI 9.64–12.36) to 47% (95% CI 43.6–50.3). In patients discharged from hospital in 2007, postfracture prescribing was 31.8% (95% CI 28.66–35.02) at 12 months, increasing to 50.3% (95% CI 46.6–53.9) at 24 months. The highest rate of prescribing was in the 65- to 69-year age group [odds ratio (OR) 8.51, 95% CI 1.75–41.35]. Patients discharged in 2008 were eight times more likely to be treated than patients discharged in 2005 (OR 8.01, 95% CI 4.55–14.09).
The percentage of patients on antiosteoporotic treatment post fracture increased significantly from 2005 to 2008. This may be largely due to the introduction of the Osteoporosis Clinic to the hospital in 2005.
KeywordsOsteoporosis Prescribing Fragility fractures Linkage Datasets
- 1.International Osteoporosis Foundation, http://www.iofbonehealth.org/facts-and-statistics.html#factsheet-category-22.
- 2.Haentjens P, Autier P, Collins J, Velkeniers B, Vanderschueren D, Boonen S (2003) Colles fracture, spine fracture, and subsequent risk of hip fracture in men and women: a meta-analysis. J Bone Jt Surg 85A:1936–1943Google Scholar
- 5.Report of the National Steering Group on the Prevention of Falls in Older People and the Prevention and Management of Osteoporosis throughout Life, 2008, Strategy to Prevent Falls and Fractures in Ireland's Ageing Population, http://www.hse.ie/eng/Publications/services/Older/Strategy_to_Prevent_Falls_and_Fractures_in_Ireland%e2%80%99s_Ageing_Population_-_Full_report.pdf.
- 14.Kamel HK, Hussain MS, Tariq S, Perry HM 111 and Morley JE (2000) Failure to diagnose and treat osteoporosis in elderly patienst hospitalized with hip fracture, Am J Med 109(4):326–328 Google Scholar
- 18.Solomon DH, Morris C, Cheng H and et al. (2005) Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions., Mayo Clin Proc, 194-202.Google Scholar
- 20.Health Service Executive (2008) Statistical analysis of claims and payments, national shared services primary care reimbursement Service. Google Scholar
- 23.Simonelli C, Killeen K, Mehle S, et al. (2002) Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons, Mayo Clinic Proc, 334-8.Google Scholar
- 24.The National Institute of Clinical Excellence, 2008, Osteoporosis - secondary prevention including strontium ranelate, http://guidance.nice.org.uk/TA161.
- 25.The National Institute of Clinical Excellence (2008) Osteoporosis - primary prevention: alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women, http://guidance.nice.org.uk/TA160.
- 29.Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral efficacy with risedronate therapy (VERT) study group. JAMA 282:1344–1352CrossRefPubMedGoogle Scholar
- 30.Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral efficacy with risedronate therapy (VERT) study group. Osteoporos Int 11:83–91CrossRefPubMedGoogle Scholar
- 31.Stevenson M, Lloyd Jones M, De Nigris E, Brewer N, Davis S, Oakley J (2005) A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 9:1–160PubMedGoogle Scholar